Project Number GC-2013255 Agency/Funding Organization Alzheimer's Drug Discovery Foundation Funding Year 2016 View Full Project Details for Ryanodine receptor inhibitors as a treatment for AD Research Categorization Primary Disease / Condition Alzheimer's Disease CADRO Category C. Translational Research and Clinical Interventions 4. Non-clinical Drug Development (small molecules and biologics) m. Synaptic Plasticity/Neuroprotection Researcher and Organization Principal Investigator STUTZMANN, GRACE Principal Investigator First Name GRACE Principal Investigator Last Name STUTZMANN Awardee Organization NeuroLucent, Inc Awardee State Illinios Contact PI Country United States Project Detail Funding Opportunity Announcement Preclinical RFP FY Overall Cost $308,985 Funding Organization Agency/Funding Organization Alzheimer's Drug Discovery Foundation Funding Organization Country United States
